Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Celebrating a major milestone for one of Europe’s biggest type 1 diabetes research cooperations: The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) has successfully screened 100,000 newborns across Europe (including over 7500 newborns in the Thames Valley) for an increased genetic risk of developing type 1 diabetes.

Celebrating a major milestone! Our researchers contribute to the international success of the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD). 100k babies across Europe (inc 7500 newborns in Thames Valley) have now been successfully screened for an increased risk of developing type 1 diabetes.

Researchers from the Thames Valley contribute to international success

It is a major milestone for one of Europe’s biggest type 1 diabetes research cooperations: The international platform GPPAD (“The Global Platform for the Prevention of Autoimmune Diabetes”) has successfully screened 100,000 newborns across Europe (including over 7500 newborns in the Thames Valley) for an increased genetic risk of developing type 1 diabetes. Participant number 100,000 is two-week-old Arthur from Dresden, Germany.

If an increased risk is detected, the children are offered to take part in a prevention trial with oral insulin (‘POInT’). The goal: to delay or even prevent the manifestation of the autoimmune disease type 1 diabetes.

Study sites in five European countries (Germany, Belgium, Poland, Sweden and Great Britain) started working on the innovative trial in November 2017, among them the research team around Dr. Manu Vatish, Chief Investigator of the INGR1D study. “We are thrilled that we have now screened 100,000 children with GPPAD and are grateful to all the hospitals and clinics involved”, Dr. Vatish says. “This number shows us that families have great interest in learning about their children’s risk status. It also means we are right on track towards the target of screening 330,000 newborns Europe-wide by 2022. And of course we are hopeful that our treatment approach of the prevention trial ‘POInT’ works. This would mean a big step towards our vision of a world without type 1 diabetes. But already today the families benefit greatly from early detection – through counseling and the excellent medical care that all of our study sites provide. Even if some of the children should develop type 1 diabetes at some point, the families will avoid possible grave complications and therefore improve the general course of the disease.”

The Meiringer family, whose twins Ben and Daniel participate in the POINT study, adds: “When we learned about the possibility to screen for an increased genetic risk for type 1 diabetes, we were quickly convinced to have our children tested. It is reassuring to know that we’re doing everything we can to increase the chance that they will not have to live with this disease – and of course we’re happy to support the research. At the very least we’re helping other families in the future who are in the same place as us.”

Surplus blood from a baby’s newborn bloodspot screening card (taken on day five of a child’s life) is used for the screening. Participation is free and available for newborns up to the age of 3 months. Currently there are 317 young participants enrolled in the prevention trial ‘POInT’ – that is a third of all children for whom an increased risk has been detected.

“We’re so grateful for the investigators, midwives, nurses, and all those who are committed to shedding light on how type 1 diabetes develops and paving the pathway to life without its burdens,” said Gina Agiostratidou, PhD, Type 1 Diabetes Program Director at The Leona M. and Harry B. Helmsley Charitable Trust, the funder of GPPAD. “In 2014, the GPPAD investigators and Helmsley started to work together to build a new kind of platform for type 1 diabetes trials focused on preventing this lifelong chronic disease from developing. We’re excited to continue our collaboration to make our shared vision of winning the battle against type 1 diabetes a reality.

You can read further information on GPPAD here.

------------

Type 1 diabetes: Type 1 diabetes is an autoimmune disease which means that the immune system attacks and destroys insulin-producing “beta cells” in the pancreas. Insulin is a vital hormone that transports sugar attained from ingested food from the blood into the cells. If the body cannot produce enough insulin, sugar will accumulate in the blood after a meal. This can lead to life-threatening metabolism disruptions and people with type 1 diabetes must therefore take insulin injections for life. However, even patients receiving good treatment may suffer from various health issues related to the autoimmune disease. The average life expectancy of a child with type 1 diabetes is reduced by 14 to 18 years.

GPPAD: The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) was initiated in 2015. It provides an international infrastructure that enables type 1 diabetes primary prevention trials. These trials are built around programs that identify infants with an elevated genetic predisposition for type 1 diabetes, and aim to reduce the incidence of the beta-cell autoimmunity that precedes clinical diabetes in children. The research is focused on newborn screening in order to identify at-risk children before an autoimmune attack sets in. GPPAD is funded by The Leona M. and Harry B. Helmsley Charitable Trust.

POInT: POInT (Primary Oral Insulin Trial) is a randomized, placebo-controlled double-blind study recruiting infants aged four to seven months. Children receive a small daily dose of insulin powder or placebo orally together with a meal until age 3. The goal is to introduce immune tolerance to insulin, as insulin and the cells that produce insulin in the pancreas are the primary targets of the destructive autoimmune reaction that characterizes type 1 diabetes. Previous studies have shown that oral administration of insulin is safe and does not affect plasma glucose levels.

Latest news

Oxford researchers part of major UK initiative to understand chronic pain

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.

Dawes-Redman Education awarded funds from Huntleigh Healthcare

The Dawes-Redman Education programme which offers virtual CTG Analysis training sessions to Obstetric consultants, antenatal and student midwifes has received generous funds from Huntleigh Healthcare for the next 3 years.

AIMDay in Women's Health 2022 - Read the Blogs

On 22nd March 2022, The University of Oxford hosted an AIMday in Women's Health at St Anne's College in Oxford. The key objective was to match the needs of organisations for new knowledge with academic expertise, with the ultimate goal of improving healthcare diagnoses & treatments for women and reproductive health.

Endometriosis: pandemic backlog risks making it even harder for women to get help

The COVID-19 pandemic has had a disproportionate and devastating impact on women’s health, according to a report from the Royal College of Obstetricians and Gynaecologists.

Similar stories

Dawes-Redman Education awarded funds from Huntleigh Healthcare

The Dawes-Redman Education programme which offers virtual CTG Analysis training sessions to Obstetric consultants, antenatal and student midwifes has received generous funds from Huntleigh Healthcare for the next 3 years.

First UK pilot study of newborn screening for spinal muscular atrophy (SMA) launched in Oxford

Spinal muscular atrophy (SMA) is a rare, but treatable, genetic disease affecting approximately 1 in 10,000 births, and it typically presents in infancy and early childhood.

Professor Collins awarded Sir Jules Thorn Translational Biomedical Research Award 2021

Professor Sally Collins has been awarded the prestigious and highly competitive Sir Jules Thorn Translational Biomedical Research Award 2021 for further translational development of the OxNNet Toolkit.

Global INTERCOVID-2022 Study launched to compare Covid-19 during pregnancy, with pregnant women without the infection.

The Oxford Maternal & Perinatal Health Institute (OMPHI) has launched the 2022 round of the global study to evaluate the effects of Covid-19 variants and vaccination in pregnancy.

Success with the Pfizer Maternal C-19 Vaccine Trial

Congratulations to Prof. Manu Vatish and the OSPREA-Gynae team on recruiting their first participant to the Pfizer maternal C-19 vaccine trial on 22nd July.

How do unborn babies and mothers communicate via the placenta?

DPhil student Neva Kandzija wins an Oxford Sparks competition to have her Placenta research transformed into a two minute animation film for free.